Global Lymphedema Diagnostics Market Size, Share, Growth Analysis Report - Forecast 2034

Lymphedema Diagnostics Industry Prospective:

The global lymphedema diagnostics market size was worth around USD 37.19 Billion in 2024 and is predicted to grow to around USD 87.32 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 8.2% between 2025 and 2034. The report analyzes the global lymphedema diagnostics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the lymphedema diagnostics industry.

Request Free Sample

Lymphedema Diagnostics Market: Overview

Lymphedema is a medical condition that is caused by lymphatic system damage, trauma, or congenital defects. When the damage develops greatly and the lymphatic fluid goes beyond the lymphatic transportation capacity, swelling results in the tissues of the affected area as an unusual amount of protein-rich fluid. There are two lymphedema types, primary and secondary. At birth (congenital) or at the beginning of puberty (praecox) or in adulthood (tarda), primary lymphedema may occur. Secondary lymphedema may be caused by surgery or radiation therapy and is a common result of cancer treatments that eliminate or harm lymph nodes or vessels.

Key Insights

• As per the analysis shared by our research analyst, the global lymphedema diagnostics market is estimated to grow annually at a CAGR of around 8.2% over the forecast period (2025-2034).
• Regarding revenue, the global lymphedema diagnostics market size was valued at around USD 37.19 Billion in 2024 and is projected to reach USD 87.32 Billion by 2034.
• The lymphedema diagnostics market is projected to grow at a significant rate due to Growing awareness and diagnosis of lymphatic disorders and rising cancer survival rates drive market growth. Advances in imaging and diagnostic technologies support adoption.
• Based on Technology, the Lymphoscintigraphy segment is expected to lead the global market.
• On the basis of Disease Type, the Primary Lymphedema segment is growing at a high rate and will continue to dominate the global market.
• Based on the End-user, the Hospitals segment is projected to swipe the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

Lymphedema Diagnostics Market: Growth Factors

Growing incidences of cancer and lymphedema to boost the global market trends

Rise in the occurrence of cancer and lymphedema along with technological innovations in diagnostic imaging modalities will scale up the expansion of the global lymphedema diagnostics market. Rise in the allocation of funds by private-public organizations in research activities related to lymphedema will proliferate the growth of the global market. Surging focus on improving healthcare quality will further accentuate the expansion of the market space globally. An increase in chronic disorders will expand the scope of growth of the global market in the years ahead. Rise in the number of product approvals will prompt the global market size in the coming decade. For instance, in the first quarter of 2020, AIROS Medical, Inc., a key medical device manufacturer based in the U.S., received approval from the U.S. FDA for its AIROS 8 sequential compression treatment equipment.

Lymphedema Diagnostics Market: Restraints

High prices of diagnostic imaging systems to restrict the global industry expansion by 2034

Huge costs of diagnostic imaging tools along with restricted helium supply and shorter life of radiopharmaceuticals can downsize the expansion of the lymphedema diagnostics industry across the globe. Additionally, a rise in the demand for renovated diagnostic imaging technologies can further impact the earnings of the global industry.

Lymphedema Diagnostics Market: Opportunities

Surging acceptance of lymphedema diagnostics devices to create new growth avenues for the global market over forecast timeline

Growing demand for lymphedema diagnostics equipment in developing countries will open new growth opportunities for the lymphedema diagnostics market across the globe.

Lymphedema Diagnostics Market: Challenges

Unfavorable reimbursement policies of government can prove to be detrimental to growth of the global industry over 2025-2034

Lack of favorable compensation policies can prove to be a huge challenge for the global lymphedema diagnostics industry in the years ahead. Need for high technical expertise for operating the lymphedema diagnostics equipment can further obstruct the growth of the industry in the upcoming years.

Lymphedema Diagnostics Market: Segmentation

The global lymphedema diagnostics market is sectored into technology, disease type, end-user, and region.                

In technology terms, the global lymphedema diagnostics market is segregated into lymphoscintigraphy, near IR fluorescence imaging, MRI, and ultrasound segments. Furthermore, the lymphoscintigraphy segment, which garnered nearly two-fifths of the global market revenue in 2024, is set to register the fastest CAGR in the ensuing years. The growth of the segment during the assessment timeline can be due to the non-invasive nature and reproducibility of lymphoscintigraphy technology.

Based on the disease type, the global lymphedema diagnostics industry is sectored into cancer, cardiovascular disease, inflammatory diseases, and filariasis segments. Moreover, the cancer segment, which accumulated a major chunk of the global industry share in 2024, is set to dominate the global industry over the projected timeline. The segmental surge over the estimated timeline can be a result of a rise in the occurrence of cancer of lymphedema kind along with surging awareness about diagnosing the disease.

Based on the end-user, the lymphedema diagnostics market across the globe is divided into hospitals and diagnostic centers segments. Moreover, the hospitals segment is anticipated to dominate the global market in the years ahead. The segmental elevation over the forecast period can be due to an increment in the lymphedema diagnostic methods performed in hospitals.   

Lymphedema Diagnostics Market: Report Scope    

Lymphedema Diagnostics Market: Regional Insights

Asia-Pacific is predicted to maintain its dominant position in the global lymphedema diagnostics market over the analysis period

Asia-Pacific, which contributed about 60% of the global lymphedema diagnostics market revenue in 2022, will be a dominating region over the projected timeframe. In addition to this, the regional market expansion can be subject to a surge in the cases of chronic ailments along with the rise in the consciousness of real-time lymphedema diagnosis among the populace of the region. In addition to this, a rise in the research activities pertaining to development of lymphedema diagnostic procedures will steer the expansion of the market in the region.

North American lymphedema diagnostics industry is set to register the fastest CAGR in the upcoming years owing to the easy availability of strong healthcare systems in countries such as the U.S. Additionally, the presence of key players in the sub-continent will steer the regional industry surge in the years ahead.

Lymphedema Diagnostics Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the lymphedema diagnostics market on a global and regional basis.

The global lymphedema diagnostics market is dominated by players like:

• Bausch Health Companies
• Anacor Pharmaceuticals Inc.
• Pfizer Inc.
• Topica Pharmaceuticals Inc.
• Moberg Pharma AB
• Dr. Reddy’s Laboratories Ltd
• NovaBiotics Inc.
• GlaxoSmithKline
• Sanofi S.A.
• Merz Pharma
• Medimetriks Pharmaceuticals Inc.
• Novartis AG
• Cipla Ltd
• Allergen Inc.
• Johnson & Johnson
• Celtic Pharma
• Bayer AG
• Galderma S.A.
• and others.

The global lymphedema diagnostics market is segmented as follows;

By Technology

• Lymphoscintigraphy
• MRI
• CT Scan
• Ultrasound Imaging
• Bioimpedance Analysis
• Others

By Disease Type

• Primary Lymphedema
• Secondary Lymphedema

By End-user

• Hospitals
• Diagnostic Centers
• Research Institutes
• Specialty Clinics

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America